Pharmacogenomics of chemotherapeutic susceptibility and toxicity

Genome Medicine

Volumn 4, Issue 11, 2012, Pages

  Moen, Erika L ^a   Godley, Lucy A ^a   Zhang, Wei ^b   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

chemotherapeutics; clinical translation; genome wide association studies; International HapMap Project; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTARABINE; ERLOTINIB; FLUOROURACIL; GEFITINIB; IRINOTECAN; METHOTREXATE; NILOTINIB; PANITUMUMAB; RASBURICASE; TAMOXIFEN; TIOGUANINE; VEMURAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; DRUG SENSITIVITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LYMPHOBLASTOID CELL LINE; MEDICAL LITERATURE; MUSCULOSKELETAL DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; TREATMENT RESPONSE;

EID: 84869890136     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm391     Document Type: Review

References (92)

1. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, Feldman MW. Genetic structure of human populations. Science 2002, 298:2381-2385. 10.1126/science.1078311, 12493913.
2. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008, 299:1335-1344. 10.1001/jama.299.11.1335, 18349094.
3. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol 2012, 6:251-259. 10.1016/j.molonc.2012.01.005, 22321460.
4. Ramsey LB, Bruun GH, Yang W, Treviño LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, Sparreboom A, Mikkelsen TS, Corydon TJ, Pui CH, Evans WE, Relling MV. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012, 22:1-8. 10.1101/gr.129668.111, 3246196, 22147369.
5. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hiacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL Makamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2012, 18:577-584. 10.1158/1078-0432.CCR-11-1387, 22142827.
6. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC, Woo XY, Nagarajan N, Kumar V, Thalamuthy A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, THan H, Lim LC, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012, 18:521-528. 10.1038/nm.2713, 22426421.
7. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Droetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012, 18:5099-5109. 10.1158/1078-0432.CCR-12-1590, 22843789.
8. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010, 28:4674-4682. 10.1200/JCO.2010.28.5064, 3020700, 20876420.
9. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piñan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011, 57:612-619. 10.1002/pbc.23074, 21387541.
10. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009, 27:5972-5978. 10.1200/JCO.2008.20.4156, 2793040, 19901119.
11. Liu M, Wang L, Bongartz T, Hawse JR, Markovic SN, Schaid DJ, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Goss PE, Ingle JN, Weinshilboum RM. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res 2012, 14:R41. 10.1186/bcr3137, 3446375, 22405131.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
13. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
14. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH, Badner JA. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004, 64:4353-4356. 10.1158/0008-5472.CAN-04-0340, 15205351.
15. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines?. Eur J Cancer 2007, 43:1011-1016. 10.1016/j.ejca.2007.01.030, 17350823.
16. Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang RS, Dolan ME. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics 2011, 21:476-488. 10.1097/FPC.0b013e3283481967, 3134538, 21642893.
17. Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 2007, 5:9-14.
18. McCarty CA, Wilke RA. Biobanking and pharmacogenomics. Pharmacogenomics 2010, 11:637-641. 10.2217/pgs.10.13, 20415552.
19. Sabatti C. Avoiding false discoveries in association studies. Methods Mol Biol 2007, 376:195-211. 10.1007/978-1-59745-389-9_14, 17984547.
20. van den Oord EJ. Controlling false discoveries in genetic studies. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:637-644. 10.1002/ajmg.b.30650, 18092307.
21. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004, 5:489-496. 10.1016/S1470-2045(04)01528-1, 15288238.
22. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987, 41:18-25. 10.1038/clpt.1987.4, 3467886.
23. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178. 10.1056/NEJMra052603, 16407512.
24. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005, 293:1485-1489. 10.1001/jama.293.12.1485, 15784872.
25. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, . Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011, 89:387-391. 10.1038/clpt.2010.320, 3098761,3098761, 21270794, Clinical Pharmacogenetics Implementation Consortium.
26. Karas-Kuzelicki N, Mlinaric-Rascan I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics 2009, 10:1309-1322. 10.2217/pgs.09.78, 19663675.
27. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009, 27:2604-2614. 10.1200/JCO.2008.20.6300, 2690389, 19349540.
28. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007, 99:1290-1295. 10.1093/jnci/djm115, 17728214.
29. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006, 7:1211-1221. 10.2217/14622416.7.8.1211, 17184208.
30. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004, 40:939-950. 10.1016/j.ejca.2003.12.004, 15093568.
31. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47:2203-2206.
32. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M, . German 5-FU Toxicity Study Group Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008, 26:2131-2138. 10.1200/JCO.2006.10.4182, 18299612, German 5-FU Toxicity Study Group.
33. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?. Clin Colorectal Cancer 2010, 9:224-228. 10.3816/CCC.2010.n.033, 20920994.
34. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerflield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
35. Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008, 34:157-174. 10.1016/j.ctrv.2007.11.001, 18164821.
36. Table of Pharmacogenomic Biomarkers in Drug Labels. , http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
37. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Treviño LR, French D, Campana D, Downing FR, Evans WE, Pui CH, Devidas M, Bowman WP, Camitta BM, Willman CL, Davies SM, Borowitz MJ, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009, 301:393-403. 10.1001/jama.2009.7, 2664534, 19176441.
38. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001, 120:1689-1699. 10.1053/gast.2001.24804, 11375950.
39. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004, 5:819-834. 10.1517/14622416.5.7.819, 15469405.
40. Ansari M, Krajinovic M. Pharmacogenomics of acute leukemia. Pharmacogenomics 2007, 8:817-834. 10.2217/14622416.8.7.817, 18240908.
41. Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedihk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011, 21:679-686. 10.1097/FPC.0b013e328343dd93, 3139712, 21317831.
42. Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE, Watson VG, Wagner M, Richards KL, Province MA, McLeod HL. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 2011, 12:1407-1415. 10.2217/pgs.11.92, 3399590, 22008047.
43. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 2004, 101:11809-11814. 10.1073/pnas.0404580101, 511056, 15282376.
44. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics 2009, 3:128-142. 10.1186/1479-7364-3-2-128, 2683878, 19164090.
45. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, Dolan ME. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007, 67:5425-5433. 10.1158/0008-5472.CAN-06-4431, 2735868, 17545624.
46. International HapMap Consortium The International HapMap Project. Nature 2003, 426:789-796. 10.1038/nature02168, 14685227, International HapMap Consortium.
47. 1000 Genomes Project Consortium A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073. 10.1038/nature09534, 3042601, 20981092, 1000 Genomes Project Consortium.
48. International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320. 10.1038/nature04226, 1880871, 16255080, International HapMap Consortium.
49. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 2008, 82:631-640. 10.1016/j.ajhg.2007.12.015, 2427223, 18313023.
50. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavaré S, Deloukas P, Dermitzakis ET. Genome-wide associations of gene expression variation in humans. PLoS Genet 2005, 1:e78. 10.1371/journal.pgen.0010078, 1315281, 16362079.
51. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, Gilad Y, Pritchard JK. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol 2011, 12:R10. 10.1186/gb-2011-12-1-r10, 3091299, 21251332.
52. Fraser HB, Lam LL, Neumann SM, Kobor MS. Population-specificity of human DNA methylation. Genome Biol 2012, 13:R8. 10.1186/gb-2012-13-2-r8, 3334571, 22322129.
53. Moen EL, Mu W, Delaney SM, Wing C, McQuade J, Godley LA, Dolan ME, Zhang W. Differences in DNA methylation between African and European HapMap populations. Cancer Res 2012, doi:10.1158/1538-7445.AM2012-5010.
54. Gamazon ER, Im HK, Duan S, Lussier YA, Cox NJ, Dolan ME, Zhang W. Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One 2010, 5:e13534. 10.1371/journal.pone.0013534, 2958831, 20975837.
55. Sugawara H, Iwamoto K, Bundo M, Ueda J, Ishigooka J, Kato T. Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines. Epigenetics 2011, 6:508-515. 10.4161/epi.6.4.14876, 3100768, 21304276.
56. Åberg K, Khachane AN, Rudolf G, Nerella S, Fugman DA, Tischfield JA, van den Oord EJ. Methylome-wide comparison of human genomic DNA extracted from whole blood and from EBV-transformed lymphocyte cell lines. Eur J Hum Genet 2012, 20:953-955. 10.1038/ejhg.2012.33, 22378283.
57. Matsson P, Yee SW, Markova S, Morrissey K, Jenkins G, Xuan J, Jorgenson E, Kroetz DL, Giacomini KM. Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. Pharmacogenomics J 2012, 12:214-226. 10.1038/tpj.2011.8, 21383772.
58. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2011, doi:10.1038/tpj.2011.38.
59. O'Donnell P, Stark A. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 2012, 118:4063-4073. 10.1002/cncr.26737, 22864933.
60. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. Genetic architecture of transcript-level variation in humans. Am J Hum Genet 2008, 82:1101-1113. 10.1016/j.ajhg.2008.03.006, 2651622, 18439551.
61. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 2010, 107:9287-9292. 10.1073/pnas.1001827107, 2889115, 20442332.
62. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007, 104:9758-9763. 10.1073/pnas.0703736104, 1887589, 17537913.
63. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 2009, 113:2145-2153. 10.1182/blood-2008-05-154302, 2652364, 19109566.
64. Tallman MS. Novel therapeutic strategies for AML in 2012. Hematology 2012, 17(Suppl 1):S43-46.
65. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME. Pharmacogenomic discovery using cell-based models. Pharmacol Rev 2009, 61:413-429. 10.1124/pr.109.001461, 2802425, 20038569.
66. Mitra AK, Crews K, Pounds S, Cao X, Downing JR, Raimondi S, Campana D, Ribeiro RC, Rubnitz JE, Lamba JK. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia 2011, 25:1354-1356. 10.1038/leu.2011.74, 3238383, 21483441.
67. Ziliak D, O''Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 2011, 157:265-272. 10.1016/j.trsl.2011.01.005, 3079878, 21497773.
68. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Shuangli M, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall EV, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi KO, Brown R, Paul J, Lambrechts D, Despierre E, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011, 17:5490-5500. 10.1158/1078-0432.CCR-11-0724, 3160494,3160494, 21705454.
69. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, Jenkins GD, Abo RP, Li L, Cunningham JM, Sun Z, Yang P, Wang L. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011, 17:5801-5811. 10.1158/1078-0432.CCR-11-1133, 3167019, 21775533.
70. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007, 6:609-621. 10.1517/14740338.6.5.609, 17877447.
71. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011, 90:377-387. 10.1038/clpt.2011.115, 21814197.
72. Cox NJ, Gamazon ER, Wheeler HE, Dolan ME. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther 2012, 92:425-427. 10.1038/clpt.2012.115, 22910437.
73. Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, Maliszewska A, de Cubas AA, Comino-Mendez I, Mancikova M, Cascon A, Robledo M, Rodriguez-Antona C. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012, 18:4441-4448. 10.1158/1078-0432.CCR-12-1221, 22718863.
74. Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol 2010, 11:507-509. 10.1016/S1470-2045(10)70097-8, 20413348.
75. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011, 12:487-497. 10.2174/138920011795495321, 3110519, 21453273.
76. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012, 92:446-449. 10.1038/clpt.2012.117, 22929923.
77. Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat 2011, 32:526-531. 10.1002/humu.21454, 3352027, 21309040.
78. Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol 2005, 311:179-191.
79. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011, 89:464-467. 10.1038/clpt.2010.279, 3098762,3098762, 21270786.
80. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012, 92:467-475.
81. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012, 91:450-458. 10.1038/clpt.2011.306, 22278335.
82. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, . BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 21639808, BRIM-3 Study Group.
83. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051. 10.1200/JCO.2007.14.0707, 18421059.
84. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19:3234-3243.
85. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, . National Cancer Institute of Canada Clinical Trials Group Study BR.21 Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006, 24:3831-3837. 10.1200/JCO.2006.05.8073, 16921034, National Cancer Institute of Canada Clinical Trials Group Study BR.21.
86. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-3245. 10.1200/JCO.2007.11.5956, 17664472.
87. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169. 10.1038/sj.bjc.6603685, 2360149, 17375050.
88. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
89. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003, 37:1047-1054. 10.1345/aph.1C336, 12841818.
90. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Droetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. The Pharmacogenetics Research Network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007, 81:328-345. 10.1038/sj.clpt.6100087, 17339863.
91. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007, 13:3269-3275. 10.1158/1078-0432.CCR-06-2290, 17510208.
92. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007, 21:2311-2315. 10.1038/sj.leu.2404827, 17611564.